Their job is to successfully bring out the data. It may be, and I won’t argue on pricing. I am not trying to discuss pricing. But most CEO’s will tell you that price is not their focus.
So that can’t drive the discussion we had as to fiduciary duty with regard to any explanations owed regarding ASCO. They are clearly preparing and putting themselves in the best position possible to announce and launch, should the circumstance arise and I do believe there are enough indicators of interest in speaking and presenting to be quite optimistic that it will be soon and most likely before ASCO. But that is just my personal opinion.
News 
Market Data 
Discover 
